Vera Therapeutics (VERA) Free Cash Flow (2020 - 2026)
Vera Therapeutics posted quarterly Free Cash Flow of -$106.5 million for Q1 2026, down 95.12% year-on-year from -$2.2 billion in Q1 2025, and down 51.97% on a QoQ basis from -$70.1 million in Q4 2025.
Vera Therapeutics (VERA) has 7 years of Free Cash Flow data on file, last reported at -$106.5 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 95.12% year-over-year to -$106.5 million; the trailing twelve-month figure through Mar 2026 stood at -$293.7 million (down 87.75% YoY), and the FY2025 full-year result was -$241.7 million, down 78.2% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$106.5 million, down from -$70.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$9.0 million in Q1 2022 and bottomed at -$106.5 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$26.3 million (2023), against an average of -$37.9 million.
- The widest annual swing landed in 2022, when Free Cash Flow slumped 236.58%; it then gained 6.65% in 2023.
- A 5-year view of Free Cash Flow shows it stood at -$21.2 million in 2022, then slipped by 19.11% to -$25.2 million in 2023, then sank by 58.0% to -$39.8 million in 2024, then tumbled by 76.0% to -$70.1 million in 2025, then tumbled by 51.97% to -$106.5 million in 2026.
- The last three Free Cash Flow figures came in at -$106.5 million (Q1 2026), -$70.1 million (Q4 2025), and -$62.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Vera Therapeutics | 2.43 Bn | 1.83 Bn | - | -106.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -106.52 Mn |
| Mar 31, 2026 | -106.52 Mn |
| Dec 31, 2025 | -70.10 Mn |
| Dec 31, 2025 | -70.10 Mn |
| Sep 30, 2025 | -62.04 Mn |
| Sep 30, 2025 | -62.04 Mn |
| Jun 30, 2025 | -55.01 Mn |
| Jun 30, 2025 | -55.01 Mn |
| Mar 31, 2025 | -54.59 Mn |
| Mar 31, 2025 | -54.59 Mn |
| Dec 31, 2024 | -39.83 Mn |
| Dec 31, 2024 | -39.83 Mn |
| Sep 30, 2024 | -37.12 Mn |
| Sep 30, 2024 | -37.12 Mn |
| Jun 30, 2024 | -24.87 Mn |
| Jun 30, 2024 | -24.87 Mn |
| Mar 31, 2024 | -33.83 Mn |
| Mar 31, 2024 | -33.83 Mn |
| Dec 31, 2023 | -25.21 Mn |
| Dec 31, 2023 | -25.21 Mn |
| Sep 30, 2023 | -22.97 Mn |
| Sep 30, 2023 | -22.97 Mn |
| Jun 30, 2023 | -17.77 Mn |
| Jun 30, 2023 | -17.77 Mn |
| Mar 31, 2023 | -26.29 Mn |
| Mar 31, 2023 | -26.29 Mn |
| Dec 31, 2022 | -21.16 Mn |
| Dec 31, 2022 | -21.16 Mn |
| Sep 30, 2022 | -18.46 Mn |
| Sep 30, 2022 | -18.46 Mn |
| Jun 30, 2022 | -19.04 Mn |
| Jun 30, 2022 | -19.04 Mn |
| Mar 31, 2022 | -9.00 Mn |
| Mar 31, 2022 | -9.00 Mn |
| Dec 31, 2021 | -6.44 Mn |
| Dec 31, 2021 | -6.44 Mn |
| Sep 30, 2021 | -5.48 Mn |
| Sep 30, 2021 | -5.48 Mn |
| Jun 30, 2021 | -7.67 Mn |
| Jun 30, 2021 | -7.67 Mn |
| Mar 31, 2021 | -4.12 Mn |
| Mar 31, 2021 | -4.12 Mn |
| Dec 31, 2020 | -27.38 Mn |
| Dec 31, 2020 | -27.38 Mn |
| Sep 30, 2020 | -2.45 Mn |
| Sep 30, 2020 | -2.45 Mn |
| Jun 30, 2020 | -2.72 Mn |
| Jun 30, 2020 | -2.72 Mn |
| Mar 31, 2020 | -2.36 Mn |
| Mar 31, 2020 | -2.36 Mn |